logo-loader
viewReNeuron Group PLC

ReNeuron provides further encouraging update for potential sight-saving treatment

"We remain greatly encouraged by the continued positive efficacy we are seeing," said chief executive Olav Hellebø

eye chart
The latest group to be treated with human retinal progenitor cells comprises patients who have a greater baseline level of visual acuity (clarity of vision) than those taking part in the clinical assessment thus far

ReNeuron Group PLC (LON:RENE) shares leapt higher on Thursday after the group said its cell therapy for blindness-causing disease retinitis pigmentosa is proving efficacious in the first group of phase II patients receiving the treatment.

This follows from February’s update from which it emerged that the first three people taking part in the phase I/II study were able to read an additional three lines of a standard eye chart.

READ: ReNeuron starts dosing second cohort in eye disease trial

The latest group to be treated with human retinal progenitor cells (hRPCs) comprises patients who have a greater baseline level of visual acuity (clarity of vision) than those taking part in the clinical assessment thus far.

Further data from the trial will be shared at the Sixth Annual Retinal Cell and Gene Therapy Innovation Summit, in Vancouver, Canada, later this month.

"We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing phase I/II study with our hRPC cell therapy candidate for retinitis pigmentosa,” said ReNeuron chief executive Olav Hellebø.

“We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month."

In mid-morning trading, ReNeuron shares soared 17% higher to 142p.

 -- Adds share price --

 

Quick facts: ReNeuron Group PLC

Price: 147.5 GBX

LSE:RENE
Market: LSE
Market Cap: £46.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: 'All systems go' for ReNeuron's retinitis pigmentosa...

ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they've seen a 'rapid and profound' result in the first three patients of the second phase of clinical studies of its human retinal progenitor cells (hRPC). ''What we're seeing is hugely encouraging and I think...

1 week, 6 days ago

2 min read